TG Therapeutics (TGTX) has drawn attention after recent trading performance, with the stock showing double digit gains over the past month and past 3 months, prompting investors to reassess its current valuation and business profile.

At a latest share price of US$53.60, TG Therapeutics has seen share price momentum build over recent months, with a 30 day share price return of 37.9%, a 90 day share price return of 67.6% and a 1 year total shareholder return of 43.85%.

If you are comparing TG Therapeutics with other opportunities in the sector, this may be a useful time to look across the broader space of healthcare focused AI stocks using the 38 healthcare AI stocks.

With TG Therapeutics now trading around US$53.60 after strong recent gains, the key question is whether its current share price still reflects a discount to intrinsic value, or if the market is already pricing in future growth.

Most Popular Narrative: 4% Overvalued

The most followed narrative currently places TG Therapeutics' fair value at about $51.71, slightly below the last close of $53.60, which creates only a modest gap between price and modeled value.

The analysts have a consensus price target of $51.71 for TG Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the more bullish reporting a price target of $83.0, and the most bearish reporting a price target of just $17.0.

Want to understand why this narrative supports a higher fair value than before even with a reduced future P/E multiple? The core drivers sit in expected revenue expansion, margin assumptions and how those cash flows are discounted over time. The mix of these inputs creates a valuation path that is not obvious from the current share price.

Based on that widely followed framework, TG Therapeutics is modeled using a discount rate of about 7.3%, with revenue and earnings forecasts and an implied future earnings multiple all feeding into the $51.71 figure. With the stock trading slightly above that narrative fair value at $53.60, the current setup reflects a small premium rather than a deep discount.

Result: Fair Value of $51.71 (OVERVALUED)

However, TG Therapeutics is still heavily tied to BRIUMVI, so shifts in MS treatment preferences or tougher reimbursement could quickly challenge the current fair value story.

Another View on TG Therapeutics: Cash Flows vs Consensus

While the current analyst narrative frames TG Therapeutics as about 4% overvalued at a fair value of $51.71, the Simply Wall St DCF model points in a very different direction, implying fair value around $207.76 and suggesting the stock trades at about a 74% discount. Which lens do you find more convincing for your own thesis?

Next Steps

If this mix of cautious and optimistic signals around TG Therapeutics leaves you undecided, consider reviewing the information while the data is fresh and develop your own view using the 4 key rewards and 1 important warning sign.

Looking for more investment ideas beyond TG Therapeutics?

If TG Therapeutics has sharpened your focus, do not stop here. Use the Simply Wall St screener to explore other opportunities before the crowd spots them.

• Target potential value opportunities that combine solid fundamentals with appealing pricing by reviewing the 44 high quality undervalued stocks.
• Prioritise resilience and capital preservation by scanning companies highlighted in the 69 resilient stocks with low risk scores.
• Spot underfollowed businesses with strong underlying metrics by checking the screener containing 18 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.